References
- Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001;22:83–7.
- Coulomb-L’Hermine A, Capron F, Zou W, Piard F, Galateau F, Laurent P, . Expression of the chemokine RANTES in pulmonary Wegener’s granulomatosis. Hum Pathol 2001;32:320–6.
- Zhou Y, Huang D, Farver C, Hoffman GS. Relative importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener’s granulomatosis. J Rheumatol 2003;30:1541–7.
- Torheim EA, Yndestad A, Bjerkeli V, Halvorsen B, Aukrust P, Frøland SS. Increased expression of chemokines in patients with Wegener’s granulomatosis – modulating effects of methylprednisolone in vitro. Clin Exp Immunol 2005;140:376–83.
- Balding CE, Howie AJ, Drake-Lee AB, Savage CO. Th2 dominance in nasal mucosa in patients with Wegener’s granulomatosis. Clin Exp Immunol 2001;125:332–9.
- Lamprecht P, Bruhl H, Erdmann A, Holl-Ulrich K, Csernok E, Seitzer U, . Differences in CCR5 expression on peripheral blood CD4+CD28– T-cells and in granulomatous lesions between localized and generalized Wegener’s granulomatosis. Clin Immunol 2003;108:1–7.
- Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, . Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68:1827–32.
- Kallenberg CG. Pathogenesis of ANCA-associated vasculitis, an update. Clin Rev Allergy Immunol 2011;41:224–31.
- Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008;28:1950–9.
- Tomasson G, Lavalley M, Tanriverdi K, Finkielman JD, Davis JC Jr, Hoffman GS, ; Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Relationship between markers of platelet activation and inflammation with disease activity in Wegener’s granulomatosis. J Rheumatol 2011;38:1048–54.